Results 21 to 30 of about 23,348 (143)
The effect of 12 weeks regular physical activity and vitamin E in the treatment of non-alcoholic steatohepatitis: A pilot study [PDF]
, 2015 Background: Despite the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), there was no treatment has been proven to be effective in these common diseases.
Eslami, L. +5 more
core +7 more sources
Frontiers in Pharmacology, 2017 Pioglitazone is a type of peroxisome proliferator-activated receptor γ (PPARγ) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment.
Li Sun +8 more
doaj +1 more source
Probiotics ameliorate pioglitazone-associated bone loss in diabetic rats
Diabetology & Metabolic Syndrome, 2020 Background Pioglitazone, as a PPAR gamma agonist, is used for the management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPAR gamma activity using pioglitazone might be linked with bone mass reduction and
Ahmad Gholami +5 more
doaj +1 more source
Journal of Pharmacological Sciences, 2019 Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS).
Tsukasa Nozu +4 more
doaj +1 more source
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. [PDF]
PLoS ONE, 2014 Fetuin-A, a circulating glycoprotein synthesized in the liver, is involved in insulin resistance and type 2 diabetes. However, regulation of fetuin-A synthesis has remained obscure. We previously reported that pioglitazone treatment significantly reduced
Akinobu Ochi +10 more
doaj +1 more source
Pharmacologic approaches against advanced glycation end products (ages) in diabetic cardiovascular disease [PDF]
, 2015 Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients.
Avtaar Singh, Sanjeet Singh +6 more
core +2 more sources
PLoS ONE, 2018 BackgroundChoices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects.
Bancha Satirapoj +2 more
doaj +1 more source
Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms [PDF]
, 2018 Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes.
Guzik, Tomasz J. +2 more
core +1 more source
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]
, 2016 Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo +4 more
core +3 more sources
PPAR Research, 2018 Nonalcoholic fatty liver disease or steatohepatitis (NAFLD/NASH) is a fatty liver disease that is closely related to obesity, diabetes, and dyslipidemia. Pioglitazone, which was developed as an antidiabetic drug, is known to improve NALFD.
Hwa Young Ahn +5 more
doaj +1 more source